# SAKK 06/19 (NCT04630730)

> Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

No report yet. It can be ordered.

- Drugs tested: VPM1002BC plus atezolizumab plus cisplatin plus gemcitabine
- Indication: muscle-invasive bladder cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04630730
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Swiss Cancer Institute
- Conditions: Bladder Cancer
- Interventions: Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC); Atezolizumab; Cisplatin; Gemcitabine
- Enrollment: 46
- Primary outcome: Pathological complete remission (pCR)

## Questions raised in the commentary

_Automated from the 26 newest of 27 indexed sources (Jan 2024 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether findings merit validation in larger comparative studies
- Whether the approach can support bladder preservation and reduce cystectomy need
- Whether rBCG adds benefit to perioperative chemo-immunotherapy
- How the regimen fits with EV-P, including possible combination strategies

Also discussed: toxicity, patient selection.

## Indexed commentary on SAKK 06/19 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 26
- YouTube: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=sakk-06-19-nct04630730

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04630730", "email": "<work email>"}; the inbox owner confirms by the emailed link.